Online inquiry

IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2854MR)

This product GTTS-WQ2854MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ICOS gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_012092.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29851
UniProt ID Q9Y6W8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2854MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4967MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ1742MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ15578MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ11455MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ15092MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ5747MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ3237MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ14580MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW